ProCE Banner Activity

Treatment Options From 5 Experts for People With Multiple Myeloma: An Interactive Decision Support Tool

Tool

Did you recently receive a diagnosis of multiple myeloma, or has your myeloma recurred? Use this interactive tool to see treatment plans from 5 multiple myeloma experts by answering a series of multiple choice questions about your diagnosis.

Released: August 26, 2020

Expiration: August 25, 2021

No longer available for credit.

Share

Faculty

Sarah A. Holstein

Sarah A. Holstein, MD, PhD

Professor of Medicine
Division of Oncology and Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Carol Ann Huff

Carol Ann Huff, MD

Associate Professor of Oncology and Medicine
Division of Hematologic Malignancies
Director, Myeloma Program
Johns Hopkins University
Baltimore, Maryland

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Peter Michael Voorhees

Peter Michael Voorhees, MD

Assistant Professor of Medicine
Department of Hematology/Oncology
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Provided by

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

Celgene

Janssen administered by Scientific Affairs

Oncopeptides

Partners

GRACE

ProCE Banner

Faculty Disclosure

Primary Author

Sarah A. Holstein, MD, PhD

Professor of Medicine
Division of Oncology and Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Sarah A. Holstein, MD, PhD: consultant/advisor/speaker: AbbVie, Janssen, Takeda.

Carol Ann Huff, MD

Associate Professor of Oncology and Medicine
Division of Hematologic Malignancies
Director, Myeloma Program
Johns Hopkins University
Baltimore, Maryland

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD: consultant/advisor/speaker (paid to institution): AbbVie, Arcellx, BeiGene, Bristol Myers Squibb, Genentech Roche, Janssen, Loxo, K36, Pfizer, Sanofi, Takeda; consultant/advisor/speaker: Antengene, Oncopeptides; research funding (paid to institution): AbbVie, Allogene, Amgen, Bristol Myers Squibb, Carsgen, Genentech Roche, GSK, Regeneron, Takeda.

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Takeda; independent contractor: TG Therapeutics.

Peter Michael Voorhees, MD

Assistant Professor of Medicine
Department of Hematology/Oncology
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina